Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Change in Cash (2020 - 2025)

Historic Change in Cash for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $112000.0.

  • TScan Therapeutics' Change in Cash rose 10010.27% to $112000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $36.4 million, marking a year-over-year increase of 26483.81%. This contributed to the annual value of $45.3 million for FY2024, which is 24016.21% up from last year.
  • Per TScan Therapeutics' latest filing, its Change in Cash stood at $112000.0 for Q3 2025, which was up 10010.27% from $15.3 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Change in Cash high stood at $113.2 million for Q2 2023, and its period low was -$109.0 million during Q3 2024.
  • Its 5-year average for Change in Cash is $7.3 million, with a median of -$15.2 million in 2022.
  • Its Change in Cash has fluctuated over the past 5 years, first skyrocketed by 116738.19% in 2021, then tumbled by 55842.09% in 2023.
  • Over the past 5 years, TScan Therapeutics' Change in Cash (Quarter) stood at -$16.5 million in 2021, then fell by 4.91% to -$17.3 million in 2022, then fell by 26.36% to -$21.8 million in 2023, then skyrocketed by 308.72% to $45.6 million in 2024, then plummeted by 99.75% to $112000.0 in 2025.
  • Its last three reported values are $112000.0 in Q3 2025, $15.3 million for Q2 2025, and -$24.6 million during Q1 2025.